Back to results
US 6,586,592 B2Granted
Bis-arylsulfones
AssigneePharmacia & Upjohn Company
InventorsEric Jon Jacobsen, Stephen J. King, Kalpana M. Merchant
Life of this patent
Estimating the term…
Abstract
The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
Claims4
A compound selected from the group consisting of 5-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl) sulfonyl]phenylamine;
- 5-(1,4-diazepan-1-yl)-N-ethyl-2-[(3-fluorophenyl) sulfonyl]aniline;
- N-[5-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl)sulfonyl]phenyl]acetamide;
- N-[5-(1,4-diazepan-1-yl)-2-[phenylsulfonyl]phenyl]acetamide;
- and pharmaceutically acceptable salts thereof, wherein the compound includes an isotopic label.
1 more element
A method of performing positron emission tomography comprising:
- incorporating an isotopically labeled compound into tissue of a mammal, wherein the isotopically labeled compound is selected from 5-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl) sulfonyl]phenylamine;
- 5-(1,4-diazepan-1-yl)-N-ethyl-2-[(3-fluorophenyl) sulfonyl]aniline;
- N-[5-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl)sulfonyl]phenyl]acetamide;
- N-[5-(1,4-diazepan-1-yl)-2-[phenylsulfonyl]phenyl]acetamide;
- and pharmaceutically acceptable salts thereof, and each compound includes at least one atom selected from Carbon-11, Nitrogen-13, Oxygen-15, and Fluorine-18.
2 more elements
A method of performing nuclear magnetic resonance imaging comprising:
- incorporating a compound into tissue of a mammal, wherein the compound is selected from the group consisting of 5-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl) sulfonyl]phenylamine;
- 5-(1,4-diazepan-1-yl)-N-ethyl-2-[(3-fluorophenyl) sulfonyl]aniline;
- N-[5-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl)sulfonyl]phenyl]acetamide;
- and pharmaceutically acceptable salts thereof, provided that the fluorine atom is 19F.
1 more element
Dependencies are inferred from the claim text.